Liraglutide is named as an intervention in 3 current clinical trials in our USA, India and China registers. 2 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Novo Nordisk A/S (2). The most-studied condition is Obesity.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
NCT07244003 · ClinicalTrials.gov ↗ · T2DM (Type 2 Diabetes Mellitus)
|
Phase 4 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | China |
|
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
NCT07225816 · Obesity
|
Phase 1 | Recruiting | Novo Nordisk A/S | USA |
|
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
NCT04775082 · ClinicalTrials.gov ↗ · Obesity
|
Phase 3 | Active, closed | Novo Nordisk A/S | USA, India |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
3 single-substance products containing Liraglutide on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Novo Nordisk A/S | 2 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
| Clinical trials in India | 1 | 0 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, India and China registers name Liraglutide as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in USA and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Novo Nordisk A/S (2) and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 3 single-substance products containing Liraglutide, for example Saxenda 6 mg/ml solution for injection in pre-filled pen (Novo Nordisk A/S). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 4 entries for Liraglutide: Victoza (EU: shortage ongoing); Saxenda (EU: shortage resolved); US FDA: current; 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Liraglutide works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Liraglutide works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Liraglutide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.